panitumumab
- Generic Name
- panitumumab
- Brand Names
- Vectibix
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 339177-26-3
- Unique Ingredient Identifier
- 6A901E312A
- Background
Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent.
Panitumumab was granted FDA approval on 27 September 2006.
- Indication
美国FDA批准：用于野生型KRAS(外显子2)转移性结直肠癌(mCRC)患者的一线治疗。
- Associated Conditions
- Metastatic Colorectal Cancer (CRC)
- Associated Therapies
- -
First-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2009-12-23
- Last Posted Date
- 2014-12-04
- Lead Sponsor
- Vejle Hospital
- Target Recruit Count
- 23
- Registration Number
- NCT01038037
- Locations
- 🇩🇰
Vejle Hospital, Vejle, Denmark
Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-12-21
- Last Posted Date
- 2023-03-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 47
- Registration Number
- NCT01036087
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Panitumumab and Irinotecan for Malignant Gliomas
- First Posted Date
- 2009-11-20
- Last Posted Date
- 2013-09-04
- Lead Sponsor
- Annick Desjardins
- Target Recruit Count
- 16
- Registration Number
- NCT01017653
- Locations
- 🇺🇸
The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center, Durham, North Carolina, United States
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
- First Posted Date
- 2009-10-26
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1010
- Registration Number
- NCT01001377
- Locations
- 🇬🇧
Research Site, Wolverhampton, United Kingdom
Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
- Conditions
- Interventions
- First Posted Date
- 2009-09-25
- Last Posted Date
- 2016-01-08
- Lead Sponsor
- University of Pittsburgh
- Registration Number
- NCT00984217
- Locations
- 🇺🇸
UPMC Cancer Center - St. Margaret's, Pittsburgh, Pennsylvania, United States
🇺🇸UPMC Cancer Centers, Pittsburgh, Pennsylvania, United States
🇺🇸UPMC Cancer Center - Upper St. Clair, Pittsburgh, Pennsylvania, United States
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-09-17
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 71
- Registration Number
- NCT00979212
- Locations
- 🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸Radiological Associates of Sacramento Medical Group, Incorporated, Sacramento, California, United States
🇺🇸Mercy Cancer Center at Mercy San Juan Medical Center, Carmichael, California, United States
Preoperative Panitumumab and Radiotherapy in Rectal Cancer
- First Posted Date
- 2009-09-09
- Last Posted Date
- 2016-04-20
- Target Recruit Count
- 20
- Registration Number
- NCT00973193
- Locations
- 🇧🇪
Institute Jules Bordet, Brussels, Belgium
🇧🇪Clinique Saint Pierre, Ottignies, Belgium
🇧🇪Cliniques Universitaires Saint Luc - Université Catholique de Louvain, Brussels, Belgium
Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-05-07
- Last Posted Date
- 2015-05-15
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 71
- Registration Number
- NCT00894504
- Locations
- 🇺🇸
Family Cancer Center, Collierville, Tennessee, United States
🇺🇸Los Robles, Thousand Oaks, California, United States
🇺🇸Norton Cancer Institute, Louisville, Kentucky, United States
Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-type
- Conditions
- First Posted Date
- 2009-03-13
- Last Posted Date
- 2012-10-26
- Lead Sponsor
- Vejle Hospital
- Target Recruit Count
- 33
- Registration Number
- NCT00861120
- Locations
- 🇩🇰
Herning Regional Hospital, Herning, Denmark
🇩🇰Vejle Hospital, Dept. of Oncology, Vejle, Denmark
🇦🇹AGO Austria, Innsbruck, Austria
Biomarker - Panitumumab Response With KRAS Wild Type MCC
- First Posted Date
- 2009-03-02
- Last Posted Date
- 2015-12-02
- Lead Sponsor
- British Columbia Cancer Agency
- Target Recruit Count
- 52
- Registration Number
- NCT00853931
- Locations
- 🇨🇦
BC Cancer Agency - Abbotsford, Abbotsford, British Columbia, Canada
🇨🇦BCCA- Fraser Valley, Surrey, British Columbia, Canada
🇨🇦BC Cancer Agency, Vancouver, British Columbia, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.